salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results
29 juil. 2021 07h33 HE | Salarius Pharmaceuticals, Inc.
HOUSTON, July 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Parexel Master Logo_CMYK.png
Parexel Announces Innovative Patient Centric Partnership with Cancer Hospital Chinese Academy of Medical Sciences
28 juil. 2021 09h00 HE | Parexel International LLC
BOSTON and DURHAM, N.C., July 28, 2021 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance...
PDS Biotech Logo.png
PDS Biotechnology to Present Recent Phase 2 Human Clinical Data and On-Going Oncology Programs at Investor Conferences
28 juil. 2021 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotech Logo.png
PDS Biotechnology Announces Conference Call and Webcast to Present Second Quarter 2021 Financial Results
26 juil. 2021 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., July 26, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call
22 juil. 2021 16h05 HE | MacroGenics, Inc.
ROCKVILLE, MD, July 22, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
arvinas_logoART_lg.jpg
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471
22 juil. 2021 07h00 HE | Arvinas Inc.
– Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology therapeutics – – ARV-471 is currently in Phase 2...
Graphical Research.jpg
Monoclonal Antibodies Market Trends 2021 | North America, Europe, & APAC Industry Forecasts 2027: Graphical Research
22 juil. 2021 06h00 HE | Graphical Research
Pune, India, July 22, 2021 (GLOBE NEWSWIRE) -- The global monoclonal antibodies market size is poised to show tremendous growth during the forecast period owing to rise in the percentage of people...
Aprea logo 445pt.png
Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
21 juil. 2021 08h00 HE | Aprea Therapeutics
58% relapse free survival at 1 year post-transplant79% overall survival at 1 year post-transplant BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a...
American Oncology Network Names James Gilmore Chief Pharmacy & Procurement Officer
21 juil. 2021 07h00 HE | American Oncology Network
Fort Myers, Fla., July 21, 2021 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of cancer...
OSF HealthCare Selects Inspirata as Its Cancer Informatics Solution Provider
20 juil. 2021 09h00 HE | Inspirata, Inc.
Tampa, Florida, July 20, 2021 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology provider Inspirata announced today a new partnership with the integrated health system OSF HealthCare. ...